Eli Lilly just shared some new information. That data suggests it has an advantage against Novo Nordisk in a key market.
Zepbound outperformed Wegovy for weight loss in a new clinical trial funded by Eli Lilly & Co., Zepbound's maker.
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), AbbVie ...
and Zepbound for obesity. Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli ...
Eli Lilly is spending another $3 billion to bulk up manufacturing as the drugmaker seeks to stoke production of some blockbuster drugs and future products.
Eli Lilly & Co. approved a program to buy back as much as $15 billion of its own shares amid rapid growth fueled in part by ...
Monday looks likely to be a tough day for BioAge Labs, a US biopharma developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging.
Weight-loss drugs like Ozempic seem like a miracle. But they've also created a gold rush for online scammers and hucksters.
The proposed buyout of contract drug manufacturer Catalent won’t raise competition concerns, the European Commission said.
Technology companies continue to hold most of the top spots in the annual Management Top 250 ranking of America’s best-run ...
Bloomberg's Mike Dorning discusses former Representative Tulsi Gabbard meeting with Republican Senators who will be voting on ...
The fighters who forced Bashar al-Assad into exile began the complex task of governing the Syrian capital. New York Times reporters entering the country saw relics of the deposed regime on the ...